Skip to content

Trial · Interventional

CompletedPhase 2Results postedRegistry data

A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

NCTNCT01001104 (opens ClinicalTrials.gov in a new tab)Other id12840Other idH9X-JE-GBCZ
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
145 participants (actual)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Triple masking
Countries
1 country

Japan

Start
Oct 2009
Primary completion
Dec 2010
Completion
Dec 2010
First posted
23 Oct 2009 (estimated)
Last update posted
28 Sept 2015 (estimated)
Conditions
Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200920102011
  1. Ph 2

    A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

    NCT01001104

    Oct 2009 to Dec 2010

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.

Interventions

  • LY2189265Drug
  • PlaceboDrug

Arms4

  • Experimental

    0.75 mg LY2189265

  • Experimental

    0.5 mg LY2189265

  • Experimental

    0.25 mg LY2189265

  • Placebo comparator

    Placebo

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks

    Time frame · Baseline, 12 weeks

    Registry description

    Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). Changes in HbA1c were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

Secondary outcomes(9)

  1. Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks

    Time frame · up to 12 weeks

    Registry description

    Percentage of participants who achieved HbA1c\<7% up to the 12-week endpoint.

  2. Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks

    Time frame · up to 12 weeks

    Registry description

    Percentage of participants achieving HbA1c\<6.5% up to the 12-week endpoint.

  3. Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks

    Time frame · Baseline, 12 weeks

    Registry description

    Change in FBG following 12 weeks of therapy (that is, FBG at week 12 minus FBG at baseline). The change in FBG was analyzed using a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

  4. Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks

    Time frame · Baseline, 12 weeks

    Registry description

    SMBG levels were measured at the following 7 timepoints during the day: fasting prebreakfast, 2 hours postbreakfast, prior to lunch, 2 hours postlunch, prior to dinner, 2 hours postdinner, and prior to bed. The change in mean daily blood glucose was analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, and dose\*visit, where the participant was treated as a random effect.

  5. Change From Baseline in Total Body Weight at 12 Weeks

    Time frame · Baseline, 12 weeks

    Registry description

    Changes in body weight were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

  6. Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks

    Time frame · Baseline, 12 weeks

    Registry description

    HOMA2-S is an estimated insulin sensitivity based on updated HOMA2 model. The HOMA2 model is a computer model that estimates insulin sensitivity (%S) as percentages of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-S were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

  7. Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks

    Time frame · Baseline, 12 weeks

    Registry description

    HOMA2-B is an estimated steady state beta cell function based on updated HOMA2 model. The HOMA2 model estimates steady state pancreatic beta cell function (%B) as a percentage of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-B were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

  8. Steady-State Concentrations of LY2189265

    Time frame · 12 weeks

    Registry description

    Evaluable pharmacokinetics (PK) concentrations from all sampling time-points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at 12 weeks. The model predicted LY2189265 steady state concentrations in each dose level were calculated as estimated area under the curve (AUC)/dosing period of 168 hours. The models and model parameters were described by nonlinear, mixed-effects regression modeling (NONMEM) using the program NONMEM 7®.

  9. Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period

    Time frame · 12 weeks

    Registry description

    Assessed the percentage of participants who reported a hypoglycemic episode during the 12-week treatment period. Hypoglycemia was defined as a measured plasma glucose level of ≤70 milligrams per deciliter (mg/dL) or ≤3.9 millimoles per liter (mmol/L).

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeLeast squares mean· Baseline, 12 weeks

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks

GroupValue (percentage glycosylated hemoglobin)
0.75 mg LY2189265-1.35
0.5 mg LY2189265-1.15
0.25 mg LY2189265-0.90
Placebo-0.18
Secondary and other outcome results(7)
Secondary outcomeNumber· up to 12 weeks

Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks

GroupValue (percentage of participants)
0.75 mg LY218926577.1
0.5 mg LY218926559.5
0.25 mg LY218926547.2
Placebo10.8
Secondary outcomeNumber· up to 12 weeks

Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks

GroupValue (percentage of participants)
0.75 mg LY218926534.3
0.5 mg LY218926524.3
0.25 mg LY21892658.3
Placebo2.7
Secondary outcomeLeast squares mean· Baseline, 12 weeks

Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks

GroupValue (milligrams per deciliter (mg/dL))
0.75 mg LY2189265-37.48
0.5 mg LY2189265-28.55
0.25 mg LY2189265-29.21
Placebo-9.00
Secondary outcomeLeast squares mean· Baseline, 12 weeks

Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks

GroupValue (milligrams per deciliter (mg/dL))
0.75 mg LY2189265-48.99
0.5 mg LY2189265-53.12
0.25 mg LY2189265-40.70
Placebo-7.49
Secondary outcomeLeast squares mean· Baseline, 12 weeks

Change From Baseline in Total Body Weight at 12 Weeks

GroupValue (kilograms (kg))
0.75 mg LY2189265-0.58
0.5 mg LY2189265-0.40
0.25 mg LY21892650.41
Placebo-0.84
Secondary outcomeLeast squares mean· Baseline, 12 weeks

Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks

GroupValue (percentage insulin sensitivity (%S))
0.75 mg LY2189265-4.66
0.5 mg LY2189265-6.07
0.25 mg LY21892654.65
Placebo3.74
Secondary outcomeLeast squares mean· Baseline, 12 weeks

Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks

GroupValue (percentage beta-cell function)
0.75 mg LY218926538.63
0.5 mg LY218926526.67
0.25 mg LY218926520.04
Placebo6.94

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
PlaceboAdministered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.–0 / 3716 / 37
0.25 mg LY2189265Administered by SC injection, QW for 12 weeks.–1 / 3617 / 36
0.5 mg LY2189265Administered by SC injection, QW for 12 weeks.–0 / 3718 / 37
0.75 mg LY2189265Administered by SC injection, QW for 12 weeks.–1 / 3515 / 35

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 20 Years up to 75 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Japanese patients with type 2 diabetes with a body mass index (BMI)≥18.5 kilograms per square meter (kg/m\^2) but \<40.0 kg/m\^2. * Patients who are oral antidiabetic drug (OAD) naïve or are taking OAD monotherapy except for a dipeptidyl peptidase-4 inhibitor (DPP-IV) and are willing to discontinue their OAD. * Patients who are OAD naïve with screening glycosylated hemoglobin (HbA1c) value of 7.0% to 9.5% and randomization HbA1c value of 7.0% to 9.5%, or who are taking OAD monotherapy with screening HbA1c value of 6.0% to 8.5% and randomization HbA1c value of 7.0% to 9.5%. * Patients who have, in the opinion of the investigator, a stable weight during the 12 weeks prior to screening. Exclusion Criteria: * Patients who are currently taking prescription medications to promote weight loss * Patients who are receiving chronic systemic glucocorticoid therapy, or have received such therapy within 4 weeks immediately prior to screening. * Patients who have a known clinically significant gastrointestinal disorder, have undergone excision of all or any part of the gastrointestinal tract, have undergone gastric bypass surgery for treatment of obesity, or chronically take drugs that directly influence gastrointestinal motility. * Patients who have poorly controlled hypertension, renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension. * Patients who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis or acute pancreatitis. Patients who have amylase and/or lipase of 1.5 times or more the upper limit of the reference range. * Have a family history, obvious clinical signs, or symptoms of medullary carcinoma of thyroid.

PepBank is a research reference. Talk to a doctor before you use any peptide.